Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/
Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of care is generally palliative.1,2 The five-year survival rates for patients with biliary tract cancer are very low, approximately 15%.6
Dr Thomas Mehrling, CEO of Mundipharma EDO added: “We are pleased that the FDA has recognised etoposide toniribate as a potential treatment for relapsed/refractory biliary tract cancer. As a company we are focused on developing treatments for rare and difficult-to-treat cancers and getting them to patients as rapidly as possible. We look forward to accelerating the development of etoposide toniribate, in conjunction with Imbrium Therapeutics, with a global Phase III trial with sites in EU, US, Australia and other countries.”
“We are pleased that the FDA has granted Orphan Drug Designation for etoposide toniribate in recognition of its potential as an important clinical advance for patients suffering from relapsed/refractory biliary tract cancer, a patient population that has limited treatment options,” said Paul Medeiros, President of Imbrium Therapeutics. “This designation represents Imbrium’s first milestone in oncology and underscores our commitment to advance the clinical development of oncology chemotherapeutics while actively collaborating to advance treatments across our therapeutic portfolio.”
Etoposide toniribate has shown encouraging data in Phase II trials and this data has been key in securing the ODD.7 This news is in addition to the European Medicines Agency (EMA) also granting orphan designation on 4 June 2014.8 As with the FDA, this designation allows protocol assistance, reduced fees and 10-years marketing exclusivity in that disease after approval. It can also lead to speedier reimbursement in many EU member states.
To find out more about this treatment or the Mundipharma EDO oncology clinical trials programme visit: www.edoncology.com/clinical-trials
-Ends-
Notes to editors:
For further information please visit https://www.edoncology.com/latest-news/
References:
1. Valle JW, et al.
Ann Oncol. 2016;27(S5):v27–v37.
2.
NCI. https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq.
Accessed 14.02.19
3. US FDA. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=671318
Accessed 14.02.19
4. ACS. https://www.cancer.org/cancer/bile-duct-cancer/about/key-statistics.html.
Accessed 14.02.19
5. ECIS. https://ecis.jrc.ec.europa.eu/.
Accessed 14.02.19
6. CCF. https://cholangiocarcinoma.org/.
Accessed 14.02.19
7. Pape UF, et al. J Clin Oncol.
2019;3(S4):264.
8. EMA. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3141270
Accessed 14.02.19
Date of Preparation: February 2019
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190222005126/en/
Contact information
Ex USA
Tiffany Fretwell
tiffany.fretwell@mundipharma.com
+44
(0) 1223 393 361
Helen Laurence
helen@makarahealth.com
Tel:
+44 (0) 23 81 247 327
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip named to Fast Company’s Annual List of the World’s Most Innovative Companies of 202419.3.2024 16:11:00 EET | Press release
Global cloud communications platform Infobip has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024. This year’s list shines a spotlight on businesses that are shaping industry and culture, and achieving remarkable milestones. Silvio Kutić, CEO at Infobip commented: “ Innovation is at the heart of what we do and we are delighted to have been recognized by Fast Company. Our technology is transforming how organizations interact with customers across the board, from automotive, retail and financial services, through to healthcare and other social services. ” Croatia’s first Unicorn, Infobip has been working with businesses to transform customer communications. Working with Uber in India, Infobip developed an AI-powered chatbot to enable customers to order rides via WhatsApp. The global-first initiative created a seamless booking experience for Uber customers. In February, Infobip joined forces with Podravka Group, a leading Croatian multinationa
ZAPI GROUP Showcases New Solutions in Material Automation at LogiMAT 202419.3.2024 16:00:00 EET | Press release
ZAPI GROUP, a global leader in electrification, announced today it is showcasing its solutions for the material handling and electrification industries at LogiMAT 2024. At the event, ZAPI GROUP is announcing the expansion of BlueBotics, a ZAPI GROUP company and leader in autonomous navigation technology. BlueBotics has partnered with Pramac, a leading global supplier of warehouse material handling equipment, and expanded its ANT server mission and fleet management software. These milestones bolster ZAPI GROUP's standing as a comprehensive autonomous navigation and AGV fleet management provider for electrification. "The expansion of BlueBotics is an exciting milestone as ZAPI GROUP continues to grow its capabilities to serve the global AGV and material handling sectors," noted Lloyd Gomm, Global Marketing Director at ZAPI GROUP. "BlueBotics’ consistent innovation in navigation software enables the company to broaden the spectrum of solutions and integrated systems available to our OEM c
Gramercy Funds Management LLC Names Emerging Markets Expert Hamad Almudhaf as Managing Director, Head of International Capital Markets19.3.2024 16:00:00 EET | Press release
Gramercy Funds Management LLC (“Gramercy”), a $6 billion, global emerging markets investment manager, today announced that Hamad Almudhaf has joined the firm in a newly created role, Head of International Capital Markets. Mr. Almudhaf will be responsible for the design and implementation of Gramercy’s international expansion strategy to further enhance the firm’s high quality investor relationships outside of the U.S. He will also have a principal responsibility for the continued development of Gramercy’s international, commercial and capital formation strategy. “We are thrilled to have Hamad join the Gramercy team in this critically important new role,” said Robert Koenigsberger, Managing Partner and Chief Investment Officer of Gramercy. “Over the last 25 years, Gramercy has successfully established the firm as a prominent global emerging markets investment management company. Hamad’s proven track record of success will further advance our leading position in emerging markets and priv
Laserfiche Announces 2024 Run Smarter® Award Winners19.3.2024 16:00:00 EET | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced the winners of the 2024 Laserfiche Run Smarter® Awards. The Laserfiche Run Smarter Awards were first launched in 2005 to honor people and organizations around the world that use Laserfiche to improve productivity, build innovative processes and achieve exceptional business results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319239427/en/ “The Run Smarter Awards acknowledge and celebrate individuals, teams, and organizations that use Laserfiche to inspire digital transformation, either within organizations, the wider Laserfiche community, or across the world,” said Karl Chan, CEO of Laserfiche. “We’re excited to recognize this year’s winners, who have innovated, developed and optimized Laserfiche solutions that drive meaningful digital experiences across multiple industries in a time of rapid techn
Reintroducing Global Blue to Retailers and Shoppers Worldwide19.3.2024 15:19:00 EET | Press release
Taking shopping further through the power of experience Over 40 years ago, Global Blue pioneered the concept of Tax Free Shopping, changing the retail landscape and empowering international shoppers worldwide. Since then, its journey has evolved, now encompassing three families of solutions: Tax Free Shopping, Payments, and Post-Purchase Solutions. Within these industries, Global Blue consistently leverages its integrated software and data to bring value at every step of the journey and take shopping further. Driven by this commitment, Global Blue teams create engaging experiences that foster connections between consumers and brands while simplifying processes, to ensure every customer journey is seamless and intuitive. Through these efforts, Global Blue enables its clients to seize business opportunities, enhance customer loyalty, boost sales, and optimize operations and costs. “At Global Blue, we firmly believe that improving the shopping journey drives performance. This renewed focu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom